



Beam ON for Proteus[®]ONE at Willis-Knighton Cancer Center

First beam for IBA's compact Proton Therapy solution, Proteus[®]ONE

Louvain-la-Neuve, Belgium, December 17, 2013 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that the first high energy, razor sharp pencil beam of IBA's new Proteus[®]ONE Compact Proton Therapy solution was produced at the Willis-Knighton Cancer Center.

The proton beam was tuned by a team of physicists and engineers led by IBA's founder and Chief Research Officer, Yves Jongen, and reached target specifications for beam size and shape at isocenter. In the coming months, the team will fine tune these results to deliver the most precise proton therapy treatments in a compact system to Willis-Knighton Cancer Center patients.

Three Proteus[®]ONE compact proton therapy solutions have been ordered to date, with patient treatments expected to start in 2014. These compact centers will quickly add to the treatment capacity of the existing centers developed by IBA. To date, IBA has helped treat over 25,000 cancer patients worldwide with proton therapy.

Yves Jongen, Chief Research Officer of IBA commented: "This is a very important milestone in the development of our compact proton therapy solution. It is the talent, experience and determination of our team that makes it possible to achieve these milestones in the development of Proteus[®]ONE and ensures that we maintain our leading edge in innovation and our position as the world's leader in the delivery of proton therapy."

Lane R. Rosen, MD, Director of Radiation Oncology at WKCC, added: "IBA and Willis-Knighton Cancer Center are demonstrating once again that a strong partnership can help bring advanced cancer care to our community. We look forward to start treating patients next year on the first Proteus[®]ONE solution."

Beth Klein, IBA VP Sales North America, shared: "We are very excited about how quickly the Proteus[®]ONE is meeting or exceeding the milestones we set for it. It will be the only compact system in the market without clinical compromise, making the highest quality proton therapy affordable for many more institutions, thereby bringing this powerful treatment to more patients. "

-----END-----



About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide are IBA systems. This includes 15 proton therapy centers in operation and 11 additional centers under development. Over 25 000 patients have been treated on IBA equipment – more than on all major competitive installations combined.

About Proteus[®] ONE*

IBA Proteus[®] ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus[®] PLUS*, developed over the years with top clinical institutions worldwide. Proteus[®] ONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT), the most advanced radiotherapy treatment modality. Proteus[®] ONE is IBA's response to make protons affordable: it is smaller, more affordable, easier to install, easier to operate and ultimately easier to finance. With Proteus[®] ONE, protons are possible for more patients worldwide.

**Proteus[®] ONE and Proteus PLUS are brand names of configurations of the Proteus[®] 235. They may include new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com



About Willis-Knighton Cancer Center

Located in Shreveport Louisiana, the Willis-Knighton Cancer Center is the region's premier cancer treatment facility. WKCC provides a wide range of treatment options for cancer patients including radiation oncology, medical oncology and hematology, surgical oncology and gynecologic oncology. The Cancer Center provides diagnostic services such as PET, X-ray, CT and laboratory. It also offers support groups, counselling, nutritional and educational resources, and community education programs.

For more information, please contact

For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager PT
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications
Amber Bielecka, Mary-Jane Elliott, Matthew Neal
+44 (0) 207 920 2333
IBA@consilium-comms.com

Willis-Knighton Cancer Center

Marilyn Joiner
Director of Marketing
(318) 212-8965
mjoiner@wkhs.com